Jørstad ØK, Steffensen LA, Eriksen K, et al. - Researchers conducted the study for describing the first 13 years of anti‐vascular endothelial growth factor (anti‐VEGF) therapy from the perspective of a public ophthalmic department serving a local community of almost one million people. Data were collected from Oslo University Hospital, Norway from 2006 through 2018. According to this retrospective registry study, the number of unique patients treated per year rose from 130 in 2006 to 3,428 in 2018. In 13 years the number of annual intravitreal injections has risen nearly 100-fold. Long-term care was given to the majority of patients. The most prevalent condition was macular degeneration. Usage of bevacizumab as first-line therapy with aflibercept reserved for resistant cases from 2013 ultimately resulted in a drug use ratio of almost 1:1.